Supplementary Data from Genetic, Pharmacogenomic, and Immune Landscapes of Enhancer RNAs Across Human Cancers

Zhao Zhang,Mei Luo,Qiang Li,Yuan Liu,Charles Lussier,Jian Zhang,Youqiong Ye,An-Yuan Guo,Leng Han

DOI: https://doi.org/10.1158/0008-5472.22431403

2023-01-01

Abstract:Supplementary Data from Genetic, Pharmacogenomic, and Immune Landscapes of Enhancer RNAs Across Human Cancers

What problem does this paper attempt to address?

Supplementary Data from Pan-Cancer Analysis of Microbiome Quantitative Trait Loci

Can Chen,Yimin Cai,Yizhuo Liu,Shuoni Chen,Yanmin Li,Fuwei Zhang,Ming Zhang,Zequn Lu,Pingting Ying,Jinyu Huang,Linyun Fan,Xiaomin Cai,Caibo Ning,Wenzhuo Wang,Yuan Jiang,Heng Zhang,Shuhui Yang,Zhihua Wang,Xiaoyang Wang,Shaokai Zhang,Chaoqun Huang,Bin Xu,Zhenming Fu,Qibin Song,Mingjuan Jin,Kun Chen,Hongda Chen,Min Dai,Xiaoping Miao,Xiaojun Yang,Ying Zhu,Jianbo Tian

DOI: https://doi.org/10.1158/0008-5472.22432556.v1

2023-01-01

Abstract:Supplementary Data from Pan-Cancer Analysis of Microbiome Quantitative Trait Loci
Genetic, Pharmacogenomic and Immune landscapes of enhancer RNAs across human cancers

Zhao Zhang,Mei Luo,Qiang Li,Yuan Liu,Charles Lussier,Jian Zhang,Youqiong Ye,An-Yuan Guo,Leng Han

DOI: https://doi.org/10.1158/0008-5472.can-21-2058

IF: 11.2

2022-01-12

Cancer Research

Abstract:Enhancer RNAs (eRNA) regulate gene expression and play critical roles in cancer. Using large-scale omics data from The Cancer Genome Atlas (TCGA), we systematically investigated the impact of genetic variants on eRNA expression and identified approximately 1 million eRNA quantitative trait loci (eRNA-QTL) as cis- and trans-acting. Over 16,000 eRNA-QTLs were associated with patient overall survival. Assessing the impact of eRNAs on more than 1,000 imputed anticancer drug responses across approximately 10,000 patients with cancer revealed more than 7 million significant associations. Furthermore, approximately 240,000 significant associations were identified between eRNA expression and immune cell abundance deconvoluted by TIMER, CIBERSORT, ImmuCellAI, and ImmuneCellGSVA. Finally, a user-friendly data portal was generated: Genetic, Pharmacogenomic, and Immune Landscapes of eRNAs (GPIeR; https://hanlab.tamhsc.edu/GPIeR/). GPIeR is a large-scale multidimensional data portal that can be used to explore eRNA-associated genetic variants, drug responses, and immune infiltration, with the purpose of facilitating functional and clinical investigations of eRNAs in cancer.SIGNIFICANCE: This study provides insights into the impact of the enhancer RNA (eRNA) landscape on patient outcome, the immune microenvironment, and drug response across cancers and develops a multidimensional data portal to facilitate eRNA research.

oncology
Supplementary Data from Risk SNP-Mediated Enhancer–Promoter Interaction Drives Colorectal Cancer through Both FADS2 and AP002754.2

Jianbo Tian,Jiao Lou,Yimin Cai,Meilin Rao,Zequn Lu,Ying Zhu,Danyi Zou,Xiating Peng,Haoxue Wang,Ming Zhang,Siyuan Niu,Yue Li,Rong Zhong,Jiang Chang,Xiaoping Miao

DOI: https://doi.org/10.1158/0008-5472.22424890.v1

2023-01-01

Abstract:Including supplementary methods, 8 figures and 5 tables
Supplementary Data from Landscape of MicroRNA Regulatory Network Architecture and Functional Rerouting in Cancer

Xu Hua,Yongsheng Li,Sairahul R. Pentaparthi,Daniel J. McGrail,Raymond Zou,Li Guo,Aditya Shrawat,Kara M. Cirillo,Qing Li,Akshay Bhat,Min Xu,Dan Qi,Ashok Singh,Francis McGrath,Steven Andrews,Kyaw Lwin Aung,Jishnu Das,Yunyun Zhou,Alessia Lodi,Gordon B. Mills,S. Gail Eckhardt,Marc L. Mendillo,Stefano Tiziani,Erxi Wu,Jason H. Huang,Nidhi Sahni,S. Stephen Yi

DOI: https://doi.org/10.1158/0008-5472.can-20-0371

2023-01-01

Abstract:Supplementary Figures and Supplementary Table S1
Comprehensive characterization genetic regulation and chromatin landscape of enhancer-associated long non-coding RNAs and their implication in human cancer

Xin Li,Xu Pan,Hanxiao Zhou,Peng Wang,Yue Gao,Shipeng Shang,Shuang Guo,Jie Sun,Zhiying Xiong,Shangwei Ning,Hui Zhi,Xia Li

DOI: https://doi.org/10.1093/bib/bbab401

IF: 9.5

2021-09-28

Briefings in Bioinformatics

Abstract:Abstract Long non-coding RNAs (lncRNAs) that emanate from enhancer regions (defined as enhancer-associated lncRNAs, or elncRNAs) are emerging as critical regulators in disease progression. However, their biological characteristics and clinical relevance have not been fully portrayed. Here, based on the traditional expression quantitative loci (eQTL) and our optimized residual eQTL method, we comprehensively described the genetic effect on elncRNA expression in more than 300 lymphoblastoid cell lines. Meanwhile, a chromatin atlas of elncRNAs relative to the genetic regulation state was depicted. By applying the maximum likelihood estimate method, we successfully identified causal elncRNAs for protein-coding gene expression reprogramming and showed their associated single nucleotide polymorphisms (SNPs) favor binding of transcription factors. Further epigenome analysis revealed two immune-associated elncRNAs AL662844.4 and LINC01215 possess high levels of H3K27ac and H3K4me1 in human cancer. Besides, pan-cancer analysis of 3D genome, transcriptome, and regulatome data showed they potentially regulate tumor-immune cell interaction through affecting MHC class I genes and CD47, respectively. Moreover, our study showed there exist associations between elncRNA and patient survival. Finally, we made a user-friendly web interface available for exploring the regulatory relationship of SNP-elncRNA-protein-coding gene triplets (http://bio-bigdata.hrbmu.edu.cn/elncVarReg). Our study provides critical mechanistic insights for elncRNA function and illustrates their implications in human cancer.

biochemical research methods,mathematical & computational biology
Supplementary Data from Distinct Immune Gene Programs Associated with Host Tumor Immunity, Neoadjuvant Chemotherapy, and Chemoimmunotherapy in Resectable NSCLC

Pedro Rocha,Jiexin Zhang,Raquel Laza-Briviesca,Alberto Cruz-Bermúdez,Neus Bota-Rabassedas,Beatriz Sanchez-Espiridon,Kazuhito Funai,Carmen Behrens,Wei Lü,Ximing Tang,Apar Pataer,Edwin R. Parra,Cara Haymaker,Junya Fujimoto,Stephen G. Swisher,John V. Heymach,Don L. Gibbons,John Lee,Boris Sepesi,Tina Cascone,Luisa M. Solis,Mariano Provencio,Ignacio I. Wistuba,Humam Kadara

DOI: https://doi.org/10.1158/1078-0432.22486923

2023-01-01

Abstract:Supplementary Data from Distinct Immune Gene Programs Associated with Host Tumor Immunity, Neoadjuvant Chemotherapy, and Chemoimmunotherapy in Resectable NSCLC
Genome-wide enhancer RNA profiling adds molecular links between genetic variation and human cancers

Yi-Min Cai,Ze-Qun Lu,Bin Li,Jin-Yu Huang,Ming Zhang,Can Chen,Lin-Yun Fan,Qian-Ying Ma,Chun-Yi He,Shuo-Ni Chen,Yuan Jiang,Yan-Min Li,Cai-Bo Ning,Fu-Wei Zhang,Wen-Zhuo Wang,Yi-Zhuo Liu…

DOI: https://doi.org/10.1186/s40779-024-00539-2

2024-06-12

Military Medical Research

Abstract:Dysregulation of enhancer transcription occurs in multiple cancers. Enhancer RNAs (eRNAs) are transcribed products from enhancers that play critical roles in transcriptional control. Characterizing the genetic basis of eRNA expression may elucidate the molecular mechanisms underlying cancers.

medicine, general & internal
Supplementary Data from Genetic Determinants of Somatic Selection of Mutational Processes in 3,566 Human Cancers

Jintao Guo,Ying Zhou,Chaoqun Xu,Qinwei Chen,Zsófia Sztupinszki,Judit Börcsök,Canqiang Xu,Feng Ye,Weiwei Tang,Jiapeng Kang,Lu Yang,Jiaxin Zhong,Taoling Zhong,Tianhui Hu,Rongshan Yu,Zoltan Szallasi,Xianming Deng,Qiyuan Li

DOI: https://doi.org/10.1158/0008-5472.22361539.v1

2023-01-01

Abstract:Supplementary Methods, Figures S1-S8, Table S1-S4
Supplementary Data from Genetically Defined, Syngeneic Organoid Platform for Developing Combination Therapies for Ovarian Cancer

Shuang Zhang,Sonia Iyer,Hao Ran,Igor Dolgalev,Shengqing Gu,Wei,Connor J.R. Foster,Cynthia A. Loomis,Narciso Olvera,Fanny Dao,Douglas A. Levine,Robert A. Weinberg,Benjamin G. Neel

DOI: https://doi.org/10.1158/2159-8290.22536016.v1

2023-01-01

Abstract:Supplementary data includes suppl methods, FigS1-8ï¼Œ Table S1-3
Supplementary Data from Aberrant RNA Splicing is a Primary Link Between Genetic Variation and Pancreatic Cancer Risk

Jianbo Tian,Can Chen,Meilin Rao,Ming Zhang,Zequn Lu,Yimin Cai,Pingting Ying,Bin Li,Haoxue Wang,Lu Wang,Yao Li,Jinyu Huang,Linyun Fan,Xiaomin Cai,Caibo Ning,Yanmin Li,Fuwei Zhang,Wenzhuo Wang,Yuan Jiang,Yizhuo Liu,Min Wang,Heng Li,Chaoqun Huang,Zhiyong Yang,Jiang Chang,Ying Zhu,Xiaojun Yang,Xiaoping Miao

DOI: https://doi.org/10.1158/0008-5472.22431436

2023-01-01

Abstract:Supplementary Data from Aberrant RNA Splicing Is a Primary Link between Genetic Variation and Pancreatic Cancer Risk
Supplementary Data from Genomic Landscapes and Hallmarks of Mutant RAS in Human Cancers

Robert B. Scharpf,Archana Balan,Biagio Ricciuti,Jacob Fiksel,Christopher Cherry,Chenguang Wang,Michele L. Lenoue-Newton,Hira A. Rizvi,James R. White,Alexander S. Baras,Jordan Anaya,Blair V. Landon,Marta Majcherska-Agrawal,Paola Ghanem,Jocelyn Lee,Leon Raskin,Andrew S. Park,Huakang Tu,Hil Hsu,Kathryn C. Arbour,Mark M. Awad,Gregory J. Riely,Christine M. Lovly,Valsamo Anagnostou

DOI: https://doi.org/10.1158/0008-5472.22433054.v1

2023-01-01

Abstract:Supplementary Data from Genomic Landscapes and Hallmarks of Mutant RAS in Human Cancers
The pharmacogenomic and immune landscape of snoRNAs in human cancers

Runhao Wang,Chengxuan Chen,Yuan Liu,Mei Luo,Jingwen Yang,Yamei Chen,Lifei Ma,Liuqing Yang,Chunru Lin,Lixia Diao,Leng Han

DOI: https://doi.org/10.1016/j.canlet.2024.217304

IF: 9.756

2024-10-19

Cancer Letters

Abstract:Small nucleolar RNAs (snoRNAs) are a class of non-coding RNAs primarily known for their role in the chemical modification of other RNAs. Recent studies suggested that snoRNAs may play a broader role in anti-cancer treatments such as targeted therapies and immunotherapies. Despite these insights, the comprehensive landscape of snoRNA associations with drug response and immunotherapy outcomes remains unexplored. In this study, we identified 79,448 and 75,185 associations between snoRNAs and drug response using data from VAEN and CancerRxTissue, respectively. Additionally, we discovered 29,199 associations between snoRNAs and immune checkpoint genes and 47,194 associations between snoRNAs and immune cell infiltrations. Sixteen snoRNAs were significantly correlated with immunotherapy objective response rate (ORR), and 92 snoRNAs showed significantly differential expression between cancers with high and low ORR. Furthermore, we identified 17 snoRNAs with significantly differential expression between cancer types with high and low immune-related adverse event (irAE) reporting odds ratio (ROR). Several snoRNAs, such as SNORD92, and SNORD83B, may represent promising biomarkers or therapeutic targets that needs further investigation. To facilitate further research, we developed a user-friendly portal, Pharmacogenomic and Immune Landscape of SnoRNA (PISNO, https://hanlaboratory.com/PISNO/ ), enabling researchers to visualize, browse, and download multi-dimensional data. This study highlights the potential of snoRNAs as biomarkers or therapeutic targets, paving the way for more effective and personalized anti-cancer treatments.

oncology
Supplementary Data 3 from Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma

Seth J. Welsh,Benjamin G. Barwick,Erin W. Meermeier,Daniel L. Riggs,Chang-Xin Shi,Yuan Xiao Zhu,Meaghen E. Sharik,Megan T. Du,Leslie D. Abrego Rocha,Victoria M. Garbitt,Caleb K. Stein,Joachim L. Petit,Nathalie Meurice,Yuliza Tafoya Alvarado,Rodrigo Fonseca,Kennedi T. Todd,Sochilt Brown,Zachery J. Hammond,Nicklus H. Cuc,Courtney Wittenberg,Camille Herzog,Anna V. Roschke,Yulia N. Demchenko,Wei-dong D. Chen,Peng Li,Wei Liao,Warren J. Leonard,Sagar Lonial,Nizar J. Bahlis,Paola Neri,Lawrence H. Boise,Marta Chesi,P. Leif Bergsagel

DOI: https://doi.org/10.1158/2643-3230.24958700.v1

2024-01-01

Abstract:Differential Accessible Regions in JJN3 and KMS11
Supplementary Data URL from an Integrated View of Copy Number and Allelic Alterations in the Cancer Genome Using Single Nucleotide Polymorphism Arrays

Xiaojun Zhao,Cheng Li,J. Guillermo Paez,Koei Chin,Pasi A. Jänne,Tzu-Hsiu Chen,Luc Girard,John Minna,David Christiani,Chris Leo,Joe W. Gray,William R. Sellers,Matthew Meyerson

DOI: https://doi.org/10.1158/0008-5472.22363572

2023-01-01

Abstract:http://research.dfci.harvard.edu/meyersonlab/snp/snp.htm
Transcriptional landscape and clinical utility of enhancer RNAs for eRNA-targeted therapy in cancer

Zhao Zhang,Joo-Hyung Lee,Hang Ruan,Youqiong Ye,Joanna Krakowiak,Qingsong Hu,Yu Xiang,Jing Gong,Bingying Zhou,Li Wang,Chunru Lin,Lixia Diao,Gordon B. Mills,Wenbo Li,Leng Han

DOI: https://doi.org/10.1038/s41467-019-12543-5

IF: 16.6

2019-10-08

Nature Communications

Abstract:Abstract Enhancer RNA (eRNA) is a type of noncoding RNA transcribed from the enhancer. Although critical roles of eRNA in gene transcription control have been increasingly realized, the systemic landscape and potential function of eRNAs in cancer remains largely unexplored. Here, we report the integration of multi-omics and pharmacogenomics data across large-scale patient samples and cancer cell lines. We observe a cancer-/lineage-specificity of eRNAs, which may be largely driven by tissue-specific TFs. eRNAs are involved in multiple cancer signaling pathways through putatively regulating their target genes, including clinically actionable genes and immune checkpoints. They may also affect drug response by within-pathway or cross-pathway means. We characterize the oncogenic potential and therapeutic liability of one eRNA, NET1e , supporting the clinical feasibility of eRNA-targeted therapy. We identify a panel of clinically relevant eRNAs and developed a user-friendly data portal. Our study reveals the transcriptional landscape and clinical utility of eRNAs in cancer.

multidisciplinary sciences
Supplementary Data from KAT6A and ENL Form an Epigenetic Transcriptional Control Module to Drive Critical Leukemogenic Gene-Expression Programs

Fangxue Yan,Jinyang Li,Jelena Milosevic,Ricardo Petroni,Suying Liu,Zhennan Shi,Salina Yuan,Janice M. Reynaga,Yuwei Qi,Joshua Rico,Sixiang Yu,Yiman Liu,Susumu Rokudai,Neil Palmisiano,Sara E. Meyer,Pamela J. Sung,Liling Wan,Fei Lan,Benjamin A. Garcia,Ben Z. Stanger,David B. Sykes,M. Andrés Blanco

DOI: https://doi.org/10.1158/2159-8290.22541240.v1

2023-01-01

Abstract:Supplementary Data from KAT6A and ENL Form an Epigenetic Transcriptional Control Module to Drive Critical Leukemogenic Gene-Expression Programs
Supplementary Data from Genetic Variants That Impact Alternative Polyadenylation in Cancer Represent Candidate Causal Risk Loci

Bin Li,Yimin Cai,Can Chen,Gaoyuan Li,Ming Zhang,Zequn Lu,Fuwei Zhang,Jinyu Huang,Linyun Fan,Caibo Ning,Yanmin Li,Wenzhuo Wang,Hui Geng,Yizhuo Liu,Shuoni Chen,Hanting Li,Shuhui Yang,Heng Zhang,Wen Tian,Zhongchao Zhu,Bin Xu,Heng Li,Haijie Li,Meng Jin,Xiaoyang Wang,Shaokai Zhang,Jiuyang Liu,Chaoqun Huang,Xiaojun Yang,Yongchang Wei,Ying Zhu,Jianbo Tian,Xiaoping Miao

DOI: https://doi.org/10.1158/0008-5472.24473766.v1

2023-01-01

Abstract:Supplementary Methods, Tables and Figures
Supplementary Data from Computational Identification of Preneoplastic Cells Displaying High Stemness and Risk of Cancer Progression

Tianyuan Liu,Xuan Zhao,Yuan Lin,Qi Luo,Shaosen Zhang,Yiyi Xi,Yamei Chen,Lin,Wenyi Fan,Jie Yang,Yuling Ma,Alok K. Maity,Yanyi Huang,Jianbin Wang,Jiang Chang,Dongxin Lin,Andrew E. Teschendorff,Chen Wu

DOI: https://doi.org/10.1158/0008-5472.22431860.v1

2023-01-01

Abstract:Supplementary Data from Computational Identification of Preneoplastic Cells Displaying High Stemness and Risk of Cancer Progression
CenhANCER: a comprehensive cancer enhancer database for primary tissues and cell lines

Zhi-Hui Luo,Meng-Wei Shi,Yuan Zhang,Dan-Yang Wang,Yi-Bo Tong,Xue-Ling Pan,ShanShan Cheng

DOI: https://doi.org/10.1093/database/baad022

2023-01-01

Database

Abstract:Abstract Enhancers, which are key tumorigenic factors with wide applications for subtyping, diagnosis and treatment of cancer, are attracting increasing attention in the cancer research. However, systematic analysis of cancer enhancers poses a challenge due to the lack of integrative data resources, especially those from tumor primary tissues. To provide a comprehensive enhancer profile across cancer types, we developed a cancer enhancer database CenhANCER by curating public resources including all the public H3K27ac ChIP-Seq data from 805 primary tissue samples and 671 cell line samples across 41 cancer types. In total, 57 029 408 typical enhancers, 978 411 super-enhancers and 226 726 enriched transcription factors were identified. We annotated the super-enhancers with chromatin accessibility regions, cancer expression quantitative trait loci (eQTLs), genotype-tissue expression eQTLs and genome-wide association study risk single nucleotide polymorphisms (SNPs) for further functional analysis. The identified enhancers were highly consistent with accessible chromatin regions in the corresponding cancer types, and all the 10 super-enhancer regions identified from one colorectal cancer study were recapitulated in our CenhANCER, both of which testified the high quality of our data. CenhANCER with high-quality cancer enhancer candidates and transcription factors that are potential therapeutic targets across multiple cancer types provides a credible resource for single cancer analysis and for comparative studies of various cancer types. Database URL http://cenhancer.chenzxlab.cn/

mathematical & computational biology
Supplementary Tables from The Open Chromatin Landscape of Non–Small Cell Lung Carcinoma

Zhoufeng Wang,Kailing Tu,Lin Xia,Kai Luo,Wenxin Luo,Jie Tang,Keying Lu,Xinlei Hu,Yijing He,Wenliang Qiao,Yongzhao Zhou,Jun Zhang,Feng Cao,Shuiping Dai,Panwen Tian,Ye Wang,Lunxu Liu,Guowei Che,Qinghua Zhou,Dan Xie,Weimin Li

DOI: https://doi.org/10.1158/0008-5472.22422308.v1

2023-01-01

Abstract:SF1:Table S1. The Clinical information and pathologic characteristics of 47 NSCLC patients and 4 non-malignant nodules patients; SF2:Table S2. Information of DNA-seq, RNA-seq, ATAC-seq and single-cell ATAC-seq; SF3:Table S3. Significant amplication and deletion regions of LUAD and LUSC samples (Genes marked in red were known cancer genes); SF4:Table S4. GREAT enrichment of common open regions; SF5:Table S5. Expression change of cluster II specific open peak related genes. SF6:Table S6. Sample Information and classification; SF7:Table S7. Sub cluster 2 specific region GREAT enrichment; SF8:Table S8. broad open chromatin region related genes; SF9:Table S9. sCOP and their accosiated DEGs; SF10:Table S10. Known important NSCLC related genes were affected by sCOP; SF11:Table S11. Joint-QTLs and Genes; SF12:Table S12. Haplotype blocks harboring both joint-QTL and GWAS lead SNP of lung cancer;

Supplementary Data from Genetic, Pharmacogenomic, and Immune Landscapes of Enhancer RNAs Across Human Cancers

Supplementary Data from Pan-Cancer Analysis of Microbiome Quantitative Trait Loci

Genetic, Pharmacogenomic and Immune landscapes of enhancer RNAs across human cancers

Supplementary Data from Risk SNP-Mediated Enhancer–Promoter Interaction Drives Colorectal Cancer through Both &lt;i&gt;FADS2&lt;/i&gt; and &lt;i&gt;AP002754.2&lt;/i&gt;

Supplementary Data from Landscape of MicroRNA Regulatory Network Architecture and Functional Rerouting in Cancer

Comprehensive characterization genetic regulation and chromatin landscape of enhancer-associated long non-coding RNAs and their implication in human cancer

Supplementary Data from Distinct Immune Gene Programs Associated with Host Tumor Immunity, Neoadjuvant Chemotherapy, and Chemoimmunotherapy in Resectable NSCLC

Genome-wide enhancer RNA profiling adds molecular links between genetic variation and human cancers

Supplementary Data from Genetic Determinants of Somatic Selection of Mutational Processes in 3,566 Human Cancers

Supplementary Data from Genetically Defined, Syngeneic Organoid Platform for Developing Combination Therapies for Ovarian Cancer

Supplementary Data from Aberrant RNA Splicing is a Primary Link Between Genetic Variation and Pancreatic Cancer Risk

Supplementary Data from Genomic Landscapes and Hallmarks of Mutant RAS in Human Cancers

The pharmacogenomic and immune landscape of snoRNAs in human cancers

Supplementary Data 3 from Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma

Supplementary Data URL from an Integrated View of Copy Number and Allelic Alterations in the Cancer Genome Using Single Nucleotide Polymorphism Arrays

Transcriptional landscape and clinical utility of enhancer RNAs for eRNA-targeted therapy in cancer

Supplementary Data from KAT6A and ENL Form an Epigenetic Transcriptional Control Module to Drive Critical Leukemogenic Gene-Expression Programs

Supplementary Data from Genetic Variants That Impact Alternative Polyadenylation in Cancer Represent Candidate Causal Risk Loci

Supplementary Data from Computational Identification of Preneoplastic Cells Displaying High Stemness and Risk of Cancer Progression

CenhANCER: a comprehensive cancer enhancer database for primary tissues and cell lines

Supplementary Tables from The Open Chromatin Landscape of Non–Small Cell Lung Carcinoma

Supplementary Data from Risk SNP-Mediated Enhancer–Promoter Interaction Drives Colorectal Cancer through Both <i>FADS2</i> and <i>AP002754.2</i>